Vasant Narasimhan will become the new CEO of Swiss medical company Novartis as Joseph Jiminez retires after eight years.
Vas Narasimhan. Image: Novartis
Swiss medical company Novartis has appointed Vasant Narasimhan to replace Joseph Jiminez as chief executive from February 2018.
Jiminez, who had previously headed up Heinz, will retire after eight years in the position. His successor has been heading up the company’s drug development unit and was also chief medical officer.
Novartis has been under pressure due to lagging sales of some of its business lines and the loss of a patent for a blood cancer treatment, although it has plans for new drugs to revive sales.
Dr Narasimhan, who is currently global head of drug development and chief medical officer at Novartis, has held numerous
For thoughtful journalism, expert insights on corporate governance and an extensive library of reports, guides and tools to help boards and directors navigate the complexities of their roles, subscribe to Board Agenda